Abstract
Brain-derived neurotrophic factor (BDNF) is important in the development and maintenance of neurons and their plasticity. Hippocampal BDNF has been implicated in Alzheimer’s disease (AD) because hippocampal levels in AD patients and AD animal models are often downregulated, suggesting that reduced BDNF contributes to AD. However, the location where hippocampal BDNF protein is most highly expressed, the mossy fiber (MF) axons of dentate gyrus granule cells (GCs), has been understudied, and not in controlled conditions. Therefore, we evaluated MF BDNF protein in the Tg2576 mouse model of AD. Tg2576 and wild-type (WT) mice of both sexes were examined at 2–3 months of age, when amyloid-β (Aβ) is present in neurons but plaques are absent, and 11–20 months of age, after plaque accumulation. As shown previously, WT mice exhibited high levels of MF BDNF protein. Interestingly, there was no significant decline with age in either the genotype or sex. Notably, MF BDNF protein was correlated with GC ΔFosB, a transcription factor that increases after 1–2 weeks of elevated neuronal activity. We also report the novel finding that Aβ in GCs or the GC layer was minimal even at old ages. The results indicate that MF BDNF is stable in the Tg2576 mouse, and MF BDNF may remain unchanged due to increased GC neuronal activity, since BDNF expression is well known to be activity dependent. The resistance of GCs to long-term Aβ accumulation provides an opportunity to understand how to protect vulnerable neurons from increased Aβ levels and therefore has translational implications.
Significance Statement
Declining hippocampal brain-derived neurotrophic factor (BDNF) has been implicated in the pathogenesis of Alzheimer’s disease (AD). However, few studies have examined where hippocampal BDNF protein has its highest concentration, the dentate gyrus granule cell (GC) axons (mossy fibers; MFs). Using the well-established Tg2576 mouse model of AD, we found that MF BDNF did not decline with age, suggesting a notable exception to the idea that reduced hippocampal BDNF contributes to AD pathobiology. We also identified that Tg2576 GC activity correlates with MF BDNF protein, consistent with the activity dependence of BDNF. In addition, Tg2576 GCs were relatively resistant to accumulation of amyloid-β, providing insight into AD resilience, which has significant therapeutic implications.
Introduction
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth factors (Barde et al., 1982; Chao et al., 1998; Teng and Hempstead, 2004). BDNF is important in neuronal development and is also critical in the adult brain, where it supports neuronal structure and plasticity (Pardon, 2010; Park and Poo, 2013). One critical brain region where BDNF is high and has been studied extensively is the hippocampus, where it is considered to contribute to learning and memory (Yamada and Nabeshima, 2004; Minichiello, 2009).
AD brain tissues show variable BDNF levels, with some increases and some decreases depending on the brain area and the cell type being investigated. In hippocampus there is not always a significant change in AD (Ferrer et al., 1999; Holsinger et al., 2000; Garzon et al., 2002; Michalski et al., 2015), although some studies have reported that BDNF protein and mRNA decline (Phillips et al., 1991; Hock et al., 2000), and data from CA1 pyramidal neurons show a robust decline across the progression of dementia that correlates with cognitive decline and neuropathology (Ginsberg et al., 2006, 2010, 2019; Mufson et al., 2007; Nagahara et al., 2009). In animal models of AD, there are both increases and decreases in hippocampal BDNF mRNA and protein levels (Burbach et al., 2004; Szapacs et al., 2004; Peng et al., 2009). Despite the often equivocal findings, many investigators conclude that reduced BDNF occurs in AD, and contributes to it (Peng et al., 2009; Xue et al., 2022).
There are numerous studies of serum BDNF in AD, but serum levels may not be directly related to brain levels (Naegelin et al., 2018). One reason is that BDNF is expressed at high concentrations in platelets (Chacon-Fernandez et al., 2016). Nevertheless, reduced serum BDNF has been commonly reported in AD (Altar et al., 2009; Erickson et al., 2010; Allen et al., 2011; Thompson Ray et al., 2011; Autry and Monteggia, 2012; Tanila, 2017). Variability may be explained by the stage of AD, because two studies showed elevated serum BDNF early in AD, at the stage of mild cognitive impairment (MCI; Laske et al., 2007; Angelucci et al., 2010) followed by a decline (Laske et al., 2007). However, others found decreased serum BDNF both in MCI and later (Yu et al., 2008; Forlenza et al., 2010).
In normal rats and mice, BDNF protein shows abundant expression in the hippocampus in the mossy fiber (MF) axons of the dentate gyrus (DG) granule cells (GCs; Conner et al., 1997; Yan et al., 1997; Dieni et al., 2012). Despite the high expression in MFs, to our knowledge only one study has examined MF BDNF in AD and that study used patient-derived tissue (Connor et al., 1997). The results suggested a decreased MF BDNF protein in AD, but there was variation in age of the patients, drug history, postmortem delay, and other factors that limited conclusions.
In the present study, we took advantage of an antibody to BDNF that shows excellent specificity and staining for MF BDNF levels (Kolbeck et al., 1999; Dieni et al., 2012). We used an established AD mouse model, Tg2576 mice, which is advantageous because there is a slow development of amyloid-β (Aβ) plaques, occurring after 6 months of age (Citron et al., 1992; Hsiao et al., 1996; Kawarabayashi et al., 2001; Jacobsen et al., 2006).Therefore, we could reliably sample early (pre-plaque, 2–3 months old) or late (post-plaque, >11 months old) stages.
The results demonstrated that BDNF protein expression was strong in the MFs in Tg2576 mice and there was no detectable age-related decline. We then asked if the reason BDNF expression remains strong over the lifespan could be related to GC neuronal activity, because BDNF expression increases with activity (Tongiorgi et al., 2000) and many AD patients and mouse models of AD exhibit increased excitability (Palop and Mucke, 2010; Chin and Scharfman, 2013; Vossel et al., 2017). In this regard the Tg2576 mouse was useful because Tg2576 mice exhibit increased excitability in vivo (Bezzina et al., 2015; Kam et al., 2016) and in GCs in vitro (Alcantara-Gonzalez et al., 2021). We found that there were high levels of the transcription factor ΔFosB within GCs in Tg2576 mice when MF BDNF expression was relatively high, supporting the idea that increased GC activity promotes BDNF activity-dependent expression and could explain MF BDNF stability.
We then asked if stable GC BDNF expression might confer protection of GCs from Aβ deposition. Indeed, GCs showed remarkably little evidence of Aβ accumulation using several Aβ antibodies, even at 20 months of age. However, adjacent hilar neurons exhibited robust Aβ accumulation, as did hippocampal pyramidal cells. In summary, these data show BDNF protein in GC MFs is stable with age in Tg2576 mice, that there is a relationship to neuronal activity and the relative resistance of GCs to Aβ accumulation.
Materials and Methods
Experimental design
The study used the Tg2576 AD mouse model, with comparisons to wild type (WT) littermates. Two ages were chosen. The first age was 2–3 months, an age when mice are adult but have no sign of extracellular plaques. In addition, mice were selected from ages 11–20 months, when plaques are robust. At each age, both sexes and genotypes were included. In some experiments, the estrous cycle stage in female mice was estimated by sampling vaginal cytology at the time of death.
Before perfusion, mice were acclimated for at least 24 h to the laboratory where perfusion would occur. After perfusion, the brain was sectioned and processed using immunohistochemistry to evaluate BDNF protein expression, DG neuronal activity and Aβ immunoreactivity, as described below.
Animal care and use
The experimental procedures were performed according to the National Institutes of Health guidelines and approved by the Institutional Animal Care and Use Committee at the Nathan Kline Institute. Mice were housed in standard mouse cages, with a 12 h light/dark cycle. Mice had food (Rodent diet 5001; LabDiet) and water ad libitum. During gestation and until weaning, mice were fed chow formulated for breeding (Formulab diet 5008; LabDiet). Mice were weaned at 23–25 d of age and then were fed a standard rodent chow after weaning (Rodent diet 5001, LabDiet). After weaning mice were housed with littermates of the same sex (maximum four mice per cage). For the experimental procedures, two ages were selected: 2–3 months (mean 98.5 ± 5.4 d; range 70–101, n = 12) and 11–20 months (mean 451.8 ± 23 d; range 337–611, n = 20). Ages in the Results that are in months were calculated by dividing the age in days by 30.3 because the average number of days/month is 30.3.
Breeding and genotyping
Tg2576 mice express human APP695 with the Swedish (Lys670Arg, Met671Leu) mutations driven by the hamster prion protein promoter (Hsiao et al., 1996). They were bred in-house from male heterozygous Tg2576 and female nontransgenic mice (C57BL6/SJL F1 hybrid, Stock# 100,012, Jackson Labs). The genotype was determined using an in-house protocol for detecting the APP695 gene.
Vaginal cytology
All mice were euthanized between 10:00 A.M. and 12:00 P.M. Cycle stage was estimated by assessment of vaginal cytology collected at the time of death. The characterization of the vaginal cells was based on Scharfman et al. (Scharfman et al., 2008). The cell types were defined as follows: leukocytes (round, small cells), epithelial cells (oval, intermediate-size, nucleated cells), and cornified epithelial cells (multipolar, large, nucleated cells; see Fig. 6). In young mice there was a pattern of vaginal cytology consistent with a cyclic pattern (D’Amour et al., 2015) and in old animals there was a pattern consistent with a cessation of cyclic estrous cycles, showing either a predominance of leukocytes or epithelial/cornified epithelial cells, suggesting a state of persistent diestrus or persistent estrus, respectively (Scharfman et al., 2008, 2009). In some mice, there were few cells in the vaginal sample each day. These animals were either old, and had entered reproductive senescence, or were young, and their estrous cycles may not have become regular yet. It is also possible that mice were not cycling well due to stress or other factors such as not being housed with cages of males nearby (Whitten, 1956; Scharfman et al., 2009; D’Amour et al., 2015). To quantify cell type and number, the number of visible cells in a field of view of 400 × 400 µm was manually counted using ImageJ (Schindelin et al., 2012).
Anatomy
Perfusion-fixation and sectioning
Mice were deeply anesthetized by isoflurane inhalation (NDC#07-893-1389, Patterson Veterinary) followed by urethane [(Cat#U2500, Sigma-Aldrich), 250 mg/kg; stock solution 250 mg/ml in 0.9% sodium chloride (NaCl; Cat#S9888); intraperitoneal (i.p.)]. The abdominal cavity was opened with surgical scissors, followed by the heart cavity. A 26-gauge needle was inserted into the heart, followed by perfusion with 10 ml saline (0.9% NaCl in double distilled H2O; ddH2O) using a peristaltic pump (Minipuls 1; Gilson) followed by 30 ml of cold (4°C) 4% paraformaldehyde (PFA; Cat#19210, Electron Microscopy Sciences) in 0.1 M phosphate buffer (PB; note all buffers were pH 7.4). The brains were removed immediately and postfixed in 4% PFA at 4°C. Notably, when tissue was postfixed with 4% PFA overnight, BDNF antibodies performed poorly. Therefore, shorter durations of postfixation in 4% PFA were tested (1, 2, and 3 h). Three hours of postfixation was chosen because it optimized BDNF staining by reducing PFA exposure and maintained tissue integrity during processing better than shorter postfixation times. In addition, tissue integrity was improved by transferring sections with Pasteur pipettes that were heated to melt the tip into a curved shape, instead of brushes. Sections were transferred after floating them onto the curved part of the pipette.
Sectioning
After postfixation, the brains were washed in 0.1 M PB. Before sectioning, the brains were hemisected. One hemisphere was cut in the coronal plane and the other in the horizontal plane (50-µm-thick sections) using a vibratome; (Model# VT1000p, Leica). Similar septotemporal levels were selected and processed together. The sections were 300 µm apart. The sections were collected in 0.1 M PB. Sections that were not used immediately were stored at −20°C in 30% sucrose (Cat#S8501, Sigma-Aldrich) and 30% ethylene glycol (Cat#293237, Sigma-Aldrich) diluted in 0.1 M PB. We detected no difference in sections stored in 0.1 M PB and the storage solution.
Immunohistochemistry
BDNF immunostaining: fluorescence and brightfield
BDNF protein was detected with a mouse monoclonal anti-BDNF antibody that has been validated [(Mab#9, Developmental Hybridoma Bank] using either a fluorescence or brightfield protocol. This antibody is similar qualitatively to the one that was used originally in normal rodents that demonstrated robust MF staining (Conner et al., 1997) and was characterized and validated as a mossy fiber marker (Dieni et al., 2012).
For immunofluorescence, free-floating sections were first washed in 0.1 M Tris buffered saline (TBS, three washes for 5 min each) and then blocked with 3% mouse-on-mouse blocking serum (M.O.M; Cat#MKB-2213, Vector Laboratories) in TBS for 1 h. The primary antibody was diluted in a solution of 3% bovine serum albumin (BSA; Cat#A7906, Sigma-Aldrich), 2% donkey serum (DS; D9663, Sigma-Aldrich), and 0.3% Triton X-100 (Cat#X-100, Sigma-Aldrich) in TBS to yield a final concentration of 10 µg/ml anti-BDNF. Sections were incubated for 2 nights at 4°C on a rotator (The Belly Dancer, Stovall). For detection, donkey anti-mouse IgG-488 Alexa Fluor–conjugated secondary antibody was used (1:500; Cat#A21202, Invitrogen) in a solution of 2% DS and 0.3% Triton X-100 in TBS. Sections were incubated for 1 h at room temperature (RT), washed in TBS, and then TB. Washes were three for 5 min each. Labeled sections were mounted onto glass slides and coverslipped with fluorescent mounting medium (Citofluor AF1; Cat#17970-25, Electron Microscopy Sciences).
For brightfield microscopy, free-floating sections were first washed in TBS (3 washes for 5 min each) and then treated with 0.25% H2O2 (Cat#216763, Sigma-Aldrich), in TBS for 3min. After three washes of 5 min each in TBS, sections were incubated in 0.3% Triton X-100 in TBS for 20 min at RT. Next, sections were blocked in 1% BSA, 5% normal horse serum (NHS; Cat#S-2000, Vector Laboratories), and 1.5% M.O.M in TBS for 1 h at RT. The primary antibody was diluted in a solution of 1% BSA, 5% NHS, and 0.3% Triton X-100 in TBS to yield a final concentration of 10 µg/ml anti-BDNF. Sections were incubated for 2 nights at 4°C on a rotator. Then sections were incubated in biotinylated horse anti-mouse IgG secondary antibody (1:500; Cat#BA-2000, Vector Laboratories) in 1% BSA, and 0.3% Triton X-100 in TBS for 3 h at RT, followed by Avidin-Biotin-Complex (ABC; ABC Elite kit; 1:1,000; Cat#PK-6100, Vector Laboratories) in 1% BSA in TBS for 1 h at RT. Sections were rinsed in TBS and then in Tris buffer (TB). There were 3 washes for 5 min each. Next, sections were reacted with 3,3′-diaminobenzidine (DAB; Cat#DS905, Sigma-Aldrich; 50 mg/100 ml in 0.1 M TB) in 40 µg/ml ammonium chloride (NH4Cl; Cat#A4514, Sigma-Aldrich), 2 mg/ml D(+)–glucose (Cat#G5767, Sigma-Aldrich), 10 mM nickel chloride (NiCl2; Cat#N6136, Sigma-Aldrich), 3 µg/ml glucose oxidase (Cat#G2133-50KU, Sigma-Aldrich), and then washed (3 times for 5 min each) in TB. Labeled sections were mounted on gelatin-coated slides (1% bovine gelatin; Cat#G9391, Sigma-Aldrich) and dried overnight at RT. On the next day, sections were dehydrated with increasing concentrations of ethanol (70%, 2.5 min; 95%, 2.5 min; 100%, 5 min), cleared in Xylene (4 min; Cat#534056, Sigma-Aldrich), and coverslipped with Permount (Cat#17986-01; Electron Microscopy Sciences).
Sections were examined using an upright microscope (BX61, Olympus) equipped with brightfield and fluorescence detection. Sections were photographed using a digital camera (Model RET 2000R-F-CLR-12, Q-Imaging) and acquired using ImagePro Plus, v.7.0 (Media Cybernetics). For both fluorescence and brightfield protocols, sections from WT and Tg2576 were processed and photographed together, using the same microscope and software settings. Figures were composed in Photoshop (v7.0, Adobe).
ΔFosB
Sections from WT and Tg2576 were postfixed for 1 h in 4% PFA. Free-floating sections were first washed in 0.1 M TB (3 washes for 5 min each) and treated with 1% H2O2 in TB for 3 min. After 3 washes in TB (5 min each), sections were incubated in 0.25% Triton X-100 in TB (TrisA) and subsequently in 1% BSA and 0.25% Triton X-100 in TB (TrisB), for 10 min each. Then sections were blocked in 10% normal goat serum (NGS; Cat#S-1000, Vector Laboratories), 1% BSA and 0.25% Triton X-100 in TB for 1 h at RT. The primary antibody, a rabbit monoclonal anti-ΔFosB antibody (Cat#D358R, Cell Signaling), was diluted in TrisB (final concentration, 1:1,000). Sections were incubated overnight at 4°C on a rotator. On the following day, sections were rinsed in TrisA and subsequently in TrisB for 10 min each, then incubated in biotinylated goat anti-rabbit IgG secondary antibody (1:500; Cat#BA-1000, Vector Laboratories), diluted in TrisB, for 60 min at RT, followed by 2 rinses of 10 min each in TrisA, then TrisB. Next, sections were incubated in ABC (ABC Elite kit; 1:1,000) and diluted in TrisB for 2 h at RT. Sections were rinsed 3 times in TB (5 min each) reacted with DAB (50 mg/100 ml in 0.1 M TB), and then mounted and coverslipped as for BDNF (described above). Sections were examined and photographed, and figures were prepared as for BDNF.
Aβ immunostaining
Aβ-immunofluorescence (Aβ-IF) was detected primarily with an antibody to human Aβ (McSA1) which was raised against the N-terminal fragment (residues 1–12; Grant et al., 2000). This antibody can detect the soluble and insoluble forms of Aβ, with a specificity for Aβ without labeling amyloid precursor protein (APP, Grant et al., 2000; Billings et al., 2005). We adapted a protocol from Kobro-Flatmoen et al. (2016) using free-floating sections. First, sections were postfixed in 4% PFA to improve tissue integrity during the antigen retrieval procedure. After 3 h of postfixation, sections were washed in 0.1 M PB (3 washes for 5 min each) and then treated for 3 h in 0.1 M PB (60°C). All the following washes and dilutions were performed in 0.1 M PB. Sections were incubated for 20 min in 0.5% Triton X-100. Sections were then blocked for 2 h (5% NGS) and incubated overnight on a rotator at 4°C in primary antiserum (1:1,000, mouse monoclonal antibody to Aβ; Cat#MM-015-P, MédiMabs), 3% NGS, and 0.5% Triton X-100.
Two validated, conventionally-used Aβ antibodies (Li et al., 2017; Perez et al., 2019) were used to confirm results with McSA1: a mouse monoclonal antibody to Aβ residues 1–16 (1:1,000; clone 6E10; Cat#803001, Biolegend) or a mouse monoclonal antibody to Aβ residues 17–24 (1:1,000; clone 4G8; Cat#800708, Biolegend). For all Aβ antibodies, incubation with primary antisera was followed by 2 h of incubation with secondary antibody (1:350, goat anti-mouse IgG Alexa Fluor 488; Cat#A1101, Invitrogen).
Sections were examined using a fluorescence microscope (BX61, Olympus) and photographed using a digital camera (Model# Infinity 3-6UR, Lumenera) and the Infinity 3 software (v. 6.5.6, Lumenara). As for other photography described above, sections from WT and Tg2576 were processed and photographed together, using the same microscope and software settings.
Thioflavin-S staining
Aβ plaques were detected following the protocol of Roberson et al. (2007). Sections from WT and Tg2576 were mounted on 0.1% gelatin-coated slides, incubated in a thioflavin-S solution (1% thioflavin-S, Cat#T1892, Sigma-Aldrich, in ddH2O) for 10 min at RT, dehydrated in a graded series of ethanol (80%, 4 min; 95%, 4 min; 100%, 4 min), cleared in Xylene (4 min), and coverslipped as for BDNF (described above). Sections were examined and photographed as described above for BDNF.
Quantification
BDNF
There were two methods used for quantification.
Quantification of BDNF-immunoreactivity (BDNF-ir) was done as before (Skucas et al., 2013) by first defining three regions of interest (ROIs) in the stratum lucidum (SL), the location of the BDNF-rich MF projections. These three ROIs were at the end of the MF plexus where BDNF-ir is highest. The background value was measured from an ROI in SR, where BDNF-ir is relatively weak. BDNF-ir was calculated by subtracting the background value for optical density (OD) from the average OD of the three ROIs in SL. Then, MF BNDF-ir was normalized to the background of the same section. To quantify the BDNF-ir in the dorsal hippocampus, sections were chosen in the region ranging from the septal pole to the point in the rostral–caudal axis where the hippocampus begins to descend ventrally (1.34–2.18 mm caudal distance to Bregma). Ventral sections were chosen where the outline of the DG assumes a C-shape (2.30–3.16 mm caudal distance to Bregma).
A second method of quantification examined the entire MF projection from the GCL to CA2. The background value was measured as described above. BDNF-ir was calculated by subtracting the background value from the value of the ROI of the MFs. MF BDNF-ir quantification was then done as described above.
ΔFosB
Quantification of ΔFosB-immunoreactivity (ΔFosB-ir) was done by first defining an ROI that encircled the upper blade of the GC layer (GCL). The GCL was defined as the location of packed GC somata. The borders with the hilus and inner molecular layer were defined as the location where GCs were no longer adjacent to one another, i.e., they were >1 GC cell body width apart, as previously described (Bermudez-Hernandez et al., 2017).
The level of ΔFosB immunoreactivity (ΔFosB-ir) in the GCL was quantified using ImageJ software (NIH) at 40× magnification. Images were thresholded to create a binary overlay in which ΔFosB-positive nuclei were above threshold and the background was below threshold similar to other studies of GCs stained with an antibody to Prox1 (Bermudez-Hernandez et al., 2017) or other immunocytochemical studies of c-Fos-ir GCs (Duffy et al., 2013; Moretto et al., 2017). For a GC to be considered positive, its ΔFosB-ir had to be >2× the background. Three dorsal sections were used to calculate a mean for a given mouse.
ΔFosB-ir in GCs was quantified by manually counting ΔFosB-positive cell bodies in the upper blade of DG GCL. The same threshold used to quantify ΔFosB-ir in the GCL was used to define a ΔFosB-ir positive GC.
McSA1, 6E10, and 4G8
CA1
Quantification of Aβ-IF was done by first defining three ROIs within the area CA1 cell layer that included the highest levels of fluorescence. The background value was measured by an ROI in SLM where IF was not detected. Aβ-IF was calculated by subtracting the background from the average of the values of intensity of the three ROIs. Aβ-IF for each section was then normalized [(optical density)—(background optical density]/(background optical density). This approach has also been used previously for other immunocytochemical studies (Lee et al., 2012; Skucas et al., 2013).
DG
GCs
Aβ-IF in GCs was quantified from an ROI encircling the upper blade of the GCL. The background value was measured by an ROI in SR, where the Aβ-IF is weak. Aβ-IF was calculated by subtracting the background from the average intensity of the ROI for the GCL. Aβ-IF for each section was then normalized, as described above.
Hilar cells
Aβ-IF in hilar cells was quantified by manually counting Aβ-IF cell bodies in the hilus of the DG. A positive hilar cell was defined by choosing a threshold value which was based on the value for a bright cell in the Tg2576 mice. The threshold had to be high enough so that WT hilar cells would not reach threshold. This choice of threshold was straightforward because immunofluorescence of Tg2576 hilar cells was so bright and immunofluorescence of WT hilar cells was so hard to detect (see figures). The hilus was defined as zone 4 of Amaral (1978).
To compare the immunofluorescence of CA1 and the hilus, the highest optical density measurement in the CA1 pyramidal cells was compared to the highest value for hilar cells.
Statistical analysis
All data are presented as the mean ± standard error of the mean (SEM). The statistical significance was set at p < 0.05. Statistical analyses were performed using GraphPad Prism Software (https://www.graphpad.com/scientific-software/prism/, RRID: SCR_002798).
Parametric tests were used when data fit a normal distribution, determined by the Shapiro–Wilk normality test, and variance was homogeneous, determined by the Brown–Forsythe test. An unpaired t test was used for two groups. A two-way ANOVA followed by Tukey’s multiple comparisons test were used when comparing two independent variables. Interactions of factors are not reported in the Results unless they were significant. For data that did not follow a normal distribution or showed significant heteroscedasticity, nonparametric tests were selected. The Mann–Whitney U test was used for two groups. A Kruskal Wallis test followed by Dunn’s test were used when two or three independent variables were compared.
Results
Modified procedures for BDNF immunohistochemistry
We optimized an immunohistochemical protocol that allowed us to evaluate the expression of BDNF protein of WT and Tg2576 mice. This modification included a reduced exposure to PFA and instrumenting procedures to handle the weakly fixed, and therefore fragile, tissue sections. Hippocampal sections were incubated with a highly specific affinity-purified monoclonal antibody to BDNF (see Materials and methods; Fig. 1). Two different protocols were used, one for immunofluorescence microscopy and the other for DAB brightfield illumination (Fig. 1). The results were similar for both protocols. BDNF protein expression was predominantly in the MFs (Fig. 1A,B). A similar pattern of expression was identified both in coronal (Fig. 1A) and horizontal sections (Fig. 1B).
MF BDNF protein is not significantly different in young and old Tg2576 mice
We tested the hypothesis that BDNF protein expression changed with age. For this goal we investigated BDNF-ir in Tg2576 mice and in their WT littermates at two different ages, 2–3 months, and >11 months. The early age of 2–3 months was chosen because it is considered to be an age early in the development of AD-like features such as the appearance of plaques (as explained in the Introduction). The older age of >11 months was selected because plaques have developed by that age. Initial studies of mice >11 months was limited to 11–16 months to keep the age range of the older group from being too broad. Representative examples of coronal sections from each experimental group are shown in Figure 2A and B. The groups were young WT, old WT, young Tg2576 and old Tg2576 (n = 6/group, 3 males and 3 females).
Extended Data Table 2-1
Normality and homogeneity of variance assessment for Figure 2, where MF BDNF-ir was quantified. A non-parametric test was used for the statistical analysis when either the data did not fit a normal distribution or there was significant heteroscedasticity of variance. Download Extended Data Table 2-1, DOC file.
First, we asked if there was a difference in WT and Tg2576 MF BDNF. There were no significant differences in MF BDNF-ir related to genotype when we pooled sexes (Mann–Whitney U test, p = 0.514, WT n = 12, Tg2576 n = 12; Fig. 2C1). There was no significant effect of age when we pooled genotypes (unpaired t test, p = 0.943, t = 0.072, df =22; Fig. 2C2). At young ages, WT and Tg2576 MF BDNF-ir were not significantly different (sexes pooled; unpaired t test, p = 0.392, t = 0.089, df = 10; Fig. 2C3a). MF BDNF protein in old Tg2576 mice was not significantly different from old WT mice (Mann–Whitney U test, p = 0.937, old WT n = 6, old Tg2576 n = 6; Fig. 2C3b). These data suggest that MF BDNF-ir did not decline with age.
In Figure 2D, we focused on potential sex differences with additional analyses. There were no significant effects of sex on MF BDNF protein (genotypes pooled, unpaired t test, p = 0.470, t = 0.735, df = 22; Fig. 2D1). WT and Tg2576 females were not significantly different (unpaired t test, p = 0.945, t = 0.070, df = 10, Fig. 2D2a), and WT and Tg2576 males were not significantly different either (unpaired t test, p = 0.258, t = 1.199, df = 10; Fig. 2D2b). There also did not appear to be a decline in MF BDNF-ir with age in females, because there were no significant differences in young and old females (unpaired t test, p = 0.850, t = 0.194, df = 10; Fig. 2D3a) or young and old males (unpaired t test, p = 0.747, t = 0.331, df = 10; Fig. 2D3b). The results of tests for normality and homogeneity of variance are shown in Extended Data Table 2-1.
These data were confirmed with a second method to quantify BDNF-ir. We quantified the BDNF-ir in coronal sections, measuring the entire MF projection from the GCL to CA2 (Fig. 3C). There were no significant differences in MF BDNF-ir related to genotype when we pooled sexes (unpaired t test, p = 0.666, t = 0.438, df = 22; Fig. 3A1). There was no significant effect of age when we pooled genotypes (unpaired t test, p = 0.906, t = 0.120, df = 22; Fig. 3A2). At young ages, WT and Tg2576 MF BDNF-ir were not significantly different (sexes pooled; unpaired t test, p = 0.188, t = 1.412, df = 10; Fig. 3A3a). MF BDNF protein in old Tg2576 mice was not significantly different from old WT mice (unpaired t test t test , p = 0.656, t= 0.458, df = 10; Fig. 3A3b).
Extended Data Table 3-1
Normality and homogeneity of variance assessment for Figure 3. Which also shows quantified MF BDNF-ir. Download Extended Data Table 3-1, DOC file.
When we focused on sex (Fig. 3B), the results did not show differences either. Thus, there were no significant effects of sex on MF BDNF protein (genotypes pooled, unpaired t test, p = 0.303, t = 1.055, df = 22; Fig. 3B1). WT and Tg2576 females were not significantly different (unpaired t test, p = 0.813, t = 0.242, df = 10, Fig. 3B2a), and WT and Tg2576 males were not significantly different either (unpaired t test, p = 0.706, t = 0.389, df = 10; Fig. 3B2b). There also were no significant differences in young and old females (unpaired t test, p = 0.982, t = 0.022, df = 10; Fig. 3B3a) or young and old males (unpaired t test, p = 0.873, t = 0.164, df = 10; Fig. 3B3b). The results of tests for normality and homogeneity of variance are shown in Extended Data Table 3-1.
We then asked if there would be a decline in MF BDNF-ir if older mice were used. Therefore, we used 17- to 20-month-old mice (Fig. 4A,B). We confirmed the results at younger ages, that MF BDNF protein was similar in WT and Tg2576 mice (unpaired t test, p = 0.457, t = 0.795, df = 6, Fig. 4C).
Extended Data Table 4-1
Normality and homogeneity of variance assessment for Figure 4, where >17 month-old mice and ventral MF BDNF-ir was quantified. Note that for a three-way ANOVA (F in the Table), normality evaluation was not possible because the n was 3/group. Therefore, a non-parametric test was used for statistical comparisons. Download Extended Data Table 4-1, DOC file.
In Figure 4D–F, we focused on potential differences in MF BDNF protein expression in hippocampus across the septotemporal axis. Dorsal and ventral MF BDNF-ir were not significantly different when genotypes were pooled (Mann–Whitney U test, p = 0.514, dorsal n = 24, ventral n = 20, Fig. 4D). We also did additional statistics to further analyze dorsal and ventral regions. When a two-way ANOVA was conducted with genotype and area (dorsal vs ventral) as factors, there was no significant effect of genotype (F(1,40) = 4.047, p = 0.051) or area (F(1,40) = 0.036, p = 0.553; Fig. 4E1). Similarly, no difference was found when age and area (dorsal vs ventral) were compared (Kruskal–Wallis test, age: H = 0.908, p = 0.823, dorsal n = 12/group, ventral n = 10/group; Fig. 4E2). A Kruskal–Wallis test comparing the genotype, area, and age confirmed the lack of effects (H = 4.921, p = 0.670, dorsal n = 6/group, ventral n = 5/group; Fig. 4F). The results of tests for normality and homogeneity of variance are shown in Extended Data Table 4-1. Although these results suggested that there were no detectable abnormalities in the level of MF BDNF protein in Tg2576 mice compared to WT, there could have been abnormalities of another kind or in another brain area. Indeed, we found BDNF-ir in and around extracellular plaques both in hippocampus and cortex (n = 16 old mice; Fig. 5A). As expected, no plaques were detected in WT mice (n = 16 old mice; Fig. 5B). In these sections, the antibody to BDNF was used and then tissue sections were stained for thioflavin-S to identify plaques (see Materials and methods). The results are consistent with a previous study conducted in the APP23 mouse model of AD, where BDNF mRNA and Congo Red (which can be used as a marker of plaques; (Cohen and Connors, 1987) were double-labeled in cortex (Burbach et al., 2004).
These results suggest that in the MFs, BDNF protein levels are similar in WT and Tg2576 mice. However, BDNF protein is abnormal in extracellular plaques.
MF BDNF expression in female WT and Tg2576 mice is related to estrous cycle phase
The analysis above pooled all female mice, regardless of the stage of the estrous cycle. However, previous work has shown that rat MF BDNF rises at as estrogen increases on proestrous morning, remains elevated the next morning (estrous morning) and then returns to the baseline during the subsequent days of the estrous cycle, diestrus 1 and diestrus 2 (Scharfman et al., 2003).Therefore, we reexamined MF BDNF-ir in a cohort of females where we estimated the cycle stage at the time of perfusion (young n = 4, old n = 4; WT n = 4, Tg2576 n = 4). Perfusion was done in the morning (10:00 A.M. to 12:00 P.M.). The vaginal sample was taken immediately afterwards. If a vaginal sample had primarily leukocytes, the cycle stage at the time of death was estimated to be diestrous1 or diestrous 2 morning. If epithelial or cornified epithelial cells dominated, the stage was estimated to be proestrous or estrous morning.
The results showed that MF BDNF-ir varied with estimated cycle stage (Fig. 6). Quantification of cells in the vaginal sample showed a significant correlation between the type of cells and the intensity of MF BDNF-ir. When leukocytes were numerous, BDNF-ir was relatively low, and when epithelial or cornified epithelial cells were dominant, BDNF-ir was higher (Pearson’s; r = 0.760, p = 0.028; Fig. 6B1,2). The results are consistent with an increase in MF BDNF after the proestrous morning surge in estrogen, as shown previously for normal rodents (Scharfman et al., 2003) . Interestingly, the correlative data did not show any major differences between genotypes or age (Fig. 6). MF BDNF-ir was weak when the cell density was low (Pearson’s; r = 0.898, p = 0.002; Fig. 6B3). This result could be due to several reasons. First, in 2months-old females, there may not be a well-established cycle yet. Puberty typically ends at 2 months of age so estrous cycles may not be robust at this age. A low density in old females may reflect mice entering reproductive senescence. In other mice, there may be low cellularity for other reasons (Li et al., 2018).
ΔFosB protein expression in GCs correlates with MF BDNF protein expression
ΔFosB is part of the immediate early gene protein family that is induced by neuronal activation (Minatohara et al., 2015). Its long half-life allows it to accumulate in active cells for 1–2 weeks (Nestler et al., 2001; McClung et al., 2004). In AD, ΔFosB has been shown postmortem and in murine models with mutations in APP that simulate familial AD (Chen et al., 1997, 2000; Corbett et al., 2017; You et al., 2017, 2018). These data are consistent with the evidence that there is hyperexcitability in AD and in the mouse models (Palop and Mucke, 2010; Chin and Scharfman, 2013; Vossel et al., 2017).
Figure 7A,B shows the correlation between MF BDNF protein and ΔFosB-ir in GCs. Higher levels of BDNF protein in the MFs were significantly correlated with high GC ΔFosB-ir (Pearson’s, r = 0.551, p = 0.018; Fig. 7C1). The results suggest that when GC activity was high, MF BDNF protein increased independent of genotype and sex. However, when a two-way ANOVA was conducted with genotype and age as factors, there was no significant effect of genotype (F(1,16) = 4.143, p = 0.059) or age (F(1,16) = 0.091, p = 0.767; Fig. 7C2) on the mean ΔFosB-ir. Similarly, no differences in the means were found when genotype and sex were compared (Kruskal–Wallis test, H = 5.020, p = 0.170, male n = 6/group, female n = 4/ group; Fig. 7C3).
Extended Data Table 7-1
Normality and homogeneity of variance assessment for Figure 7, where GC ΔFosB-ir was quantified. Download Extended Data Table 7-1, DOC file.
To analyze the data with a second method, we quantified the number of GCs expressing ΔFosB-ir (Fig. 7D). The results were consistent with the analysis of the GCL ΔFosB-ir using thresholding. MF BDNF protein was positively correlated with the number of ΔFosB-ir GCs (Pearson’s, r = 0.646, p = 0.003; Fig. 7D1). However, the means were not different between groups. A two-way ANOVA conducted with genotype and age as factors confirmed no significant effect of genotype (F(1,15) = 0.715, p = 0.411) or age (F(1,15) = 0.016, p = 0.902; Fig. 7D2) on mean number of ΔFosB-ir cells. Similarly, no differences were found when genotype and sex were factors (two-way ANOVA, genotype: F(1,15) = 0.251, p = 0.623; sex: F(1,15) = 0.745, p = 0.402; Fig. 7FD2). The results for tests of normality and homogeneity of variance are shown in Extended Data Table 7-1.
Aβ expression in different hippocampal subfields
Aβ is greater in area CA1 pyramidal cells of Tg2576 mice compared to WT
One would expect greater Aβ in area CA1 pyramidal cells of Tg2576 mice relative to WT and this is what we found (Fig. 8A,B). McSA1 antibody was used to detect Aβ because it detects intracellular (oligomeric) Aβ. The difference between Tg2576 and WT mice was present at both ages 2–3 and 11–17 months (Kruskal–Wallis test, H = 17.81, p = 0.0005, n = 6/group; Fig. 8C). Both female and male Tg2576 mice showed significantly more Aβ compared to WT (Kruskal–Wallis test, H = 17.47, p = 0.0006, n = 6/group; Fig. 8D). To determine if sex differences would be significant if analyzed according to age, genotypes were pooled, and a Kruskal–Wallis test was performed with age and sex as factors. There were no significant effects (H = 0.673, p = 0.879, n = 6/group; Fig. 8E). The results for tests of normality and homogeneity of variance are shown in Extended Data Table 8-1.
Extended Data Table 8-1
Normality and homogeneity of variance assessment for Figure 8, where CA1 McSA1-IF was quantified. Download Extended Data Table 8-1, DOC file.
Surprisingly, GC Aβ expression is similar in Tg2576 and WT mice
We next turned to the DG. Surprisingly, McSA1-IF was not elevated in Tg2576 GCs relative to WT (Fig. 9). When a Kruskal-Wallis test was conducted with genotype and age as factors, there was no significant effect of genotype (H = 5.380, p = 0.146, n = 6/group; Fig. 9D). Similarly, there were no significant effects of genotype or sex (Kruskal-Wallis test, H = 6.100, p = 0.107, n = 6/group; Fig. 9E). To investigate age and sex differences further we pooled genotypes and found no effects (two-way ANOVA, age: F(1,20) = 0.019, p = 0.892; sex: F(1,20) = 0.104, p = 0.751; Fig. 9F). The results were the same by a Kruskal-Wallis test with genotype, age and sex as factors (H = 8.600, p = 0.283, n = 3/group; Fig. 9C). The results for tests of normality and homogeneity of variance are shown in Extended Data Table 9-1.
Extended Data Table 9-1
Normality and homogeneity of variance assessment for Figure 9, where DG McSA1-IF was quantified. Note that for a three-way ANOVA (F in the Table), normality evaluation was not possible because the n was 3/group. Therefore, a non-parametric test was used for statistical comparisons. Download Extended Data Table 9-1, DOC file.
To confirm the results with the McSA1 antibody, we used two additional antibodies to the N-terminal epitope of Aβ (6E10 and 4G8; Fig. 10A,B). The results confirmed that Tg2576 and WT mice were not significantly different (unpaired t test; 6E10, p = 0.878, t = 0.158, df = 9; 4G8, p = 0.589, t = 0.563, df = 8; Fig. 10C,D). The results for tests of normality and homogeneity of variance are shown in Extended Data Table 10-1.
Extended Data Table 10-1
Normality and homogeneity of variance assessment for Figure 10, where 6E10-IF and 4G8-IF were quantified. Download Extended Data Table 10-1, DOC file.
Tg2576 hilar cells exhibit robust Aβ although GCs do not
Interestingly, hilar cells showed robust McSA1-IF in Tg2576 mice even though adjacent GCs did not. WT mice did not show any Aβ expression in the hilus (Fig. 11A,B). In Tg2576 mice, there was no significant effect of age on the numbers of McSA1-positive cells (unpaired t test, p = 0.054, t = 2.177, df = 10; Fig. 11C) or sex (unpaired t test, p = 0.235, t = 1.265, df = 10; Fig. 11D).
Extended Data Table 11-1
Normality and homogeneity of variance assessment for Figure 11, where horizontal DG McSA1-IF and DG/CA1 McSA1-IF were compared. Note that for a three-way ANOVA (G in the Table), normality evaluation was not possible because the n was 3/group. Therefore, a non-parametric test was used for statistical comparisons. Download Extended Data Table 11-1, DOC file.
Because hilar Aβ-IF was so strong (Fig. 11A,B), we compared CA1 and the hilus to determine if hilar cells had the highest Aβ-IF. To this end, the most intense IF in the CA1 cells was compared to the highest intensity for hilar cells, normalized to background in each case. A two-way ANOVA with location (CA1 vs hilus) and age as factors (sexes were pooled) showed no significant differences (location: F(1,20) = 0.087, p = 0.771; age: F(1,20) = 1.344, p = 0.260; Fig. 11E). When location and sex were main factors (ages were pooled), there were no significant effects either (location: F(1,20) = 0.087, p = 0.771; sex: F(1,20) = 0.210, p = 0.651; Fig. 11F). There also were no differences by Kruskal–Wallis test, (H = 6.573, p = 0.475, n = 3/group; Fig. 11G). Therefore, quantitative differences were not detected between CA1 and the hilus. The results for tests of normality and homogeneity of variance are shown in Extended Data Table 11-1.
Discussion
Summary
This study showed that MF BDNF protein does not exhibit a significant decline with age in Tg2576 mice. Even when plaques have accumulated, MF BDNF protein was not significantly different from pre-plaque ages. In addition, GCs showed elevated ΔFosB in Tg2576 mice, and it was correlated with MF BDNF protein. Potentially for these reasons, GCs showed resilience to accumulation of intracellular Aβ, despite robust Aβ in adjacent hippocampal neurons. These findings have important implications for human AD where vulnerability to amyloid plaques is considered a major contributor to pathophysiology.
MF BDNF protein did not decline with age in WT or Tg2576 mice
Our immunohistochemical studies did not detect a significant difference in MF BDNF with aging in WT or Tg2576 mice. The lack of a decline in BDNF with age in WT mice is consistent with in situ hybridization histochemistry and ELISA in hippocampus of rats where a decline with age was not observed (Croll et al., 1998). Prior studies of hippocampal BDNF in WT animals come to a similar conclusion (Lapchak et al., 1993). However, other studies suggest that BDNF declines with age in humans. The human studies may not be suggesting there is a species difference, however, because the human studies examined circulating levels of BDNF or platelet BDNF concentration, unlike the rodent studies. In humans, serum BDNF declined with age (Lommatzsch et al., 2005; Ziegenhorn et al., 2007), and this was associated with hippocampal volume loss (Erickson et al., 2010). Therefore, the idea that BDNF declines with age and this predisposes an individual to reduced function is based primarily on serum and platelet-derived BDNF. However, other pools of BDNF, notably those within the DG, may be relatively stable with age.
If BDNF declines in area CA1 or the whole hippocampus in AD, why would that not be the case in the MFs? The resistance of GCs to insult and injury could be a reason (Scharfman, 1999). The robust expression of protective BDNF is a possible explanation. GC neuropeptide Y (NPY) is also neuroprotective and upregulated by activity, so it also could be involved in GC resilience (Vezzani et al., 1999; Marty, 2000). Indeed, NPY is upregulated in GCs in many AD murine models (Palop and Mucke, 2010).
Another contributing factor to the stability of MF BDNF could be that GCs are continually being born throughout life and the new neurons would add MF BDNF to the existing MF pathway. Increased neuronal activity increases adult neurogenesis of GCs (Bengzon et al., 1997; Parent et al., 1997, 1998), potentially elevating MF BDNF as new MFs with additional BDNF are added to SL. However, with age the rate of adult neurogenesis declines (Kempermann, 2015), and progenitors become depleted in AD mouse models (Fu et al., 2019).
ΔFosB was elevated in Tg2576 GCs
In AD mouse models, there is increased excitability of GCs (Nenov et al., 2015; Kim et al., 2021; Smith et al., 2022) and GCs specifically (Minkeviciene et al., 2009; Alcantara-Gonzalez et al., 2021). When excitability is sufficiently elevated, seizures occur and the seizures increase GC ΔFosB (You et al., 2017; Fu et al., 2019; Stephens et al., 2020). Consistent with these studies, we found that Tg2576 GCs had elevated ΔFosB. Furthermore, the mice with elevated GC ΔFosB showed higher MF BDNF, and the correlation was statistically significant. Although the correlation does not prove that elevated GC activity and ΔFosB led to the increase in MF BDNF, it supports that hypothesis.
The influence of sex on MF BDNF
Our findings add insight into the influence of estrous cycle on sex differences in AD. Indeed, according to the Alzheimer’s Association (2017), the incidence of AD is higher in women than in men. About two-thirds of persons diagnosed with AD are women; research show that they also appear to suffer a greater cognitive deterioration than men at the same disease stage (for a review, Li and Singh, 2014; Laws et al., 2018). In mouse models, female mice are typically affected more than males also (Callahan et al., 2001; Schmid et al., 2019; Poon et al., 2023). Therefore, there could have been a neuroendocrinological abnormality that contributed to the worse outcome of females compared to males. An abnormality that might have adverse effects is a loss of the ability of BDNF to increase in the MFs during the estrous cycle. It has been shown that as rodents pass through the stages of the estrous cycle, MF BDNF waxes and wanes (Scharfman et al., 2003). As females undergo the preovulatory estrogen surge, MF BDNF protein rises, and it remains high until the next morning, estrous morning (Scharfman et al., 2003, 2007; Harte-Hargrove et al., 2015). In the present study, we confirmed the correlation of estrous cycle phase in female mice with MF BDNF protein expression. Thus, a lack of a relationship between the estrous cycle and BDNF is unlikely to play a role in the pathophysiology of Tg2576 mice.
One of the limitations of our findings is that the stage of the estrous cycle when MF BDNF was examined was only estimated. One vaginal sample was taken at the time of death. One sample is not sufficient to allow one to determine cycle stage definitively because a cyclic pattern can only be ascertained by many consecutive days of assessment. On the other hand, our methods were sufficient to reproduce prior findings that had daily vaginal cytologic examination for several cycles. In other words, mice with higher MF BDNF showed a vaginal cytologic result consistent with proestrous or estrous morning. Therefore, the prediction of estrous cycle stage in the present study appeared to be a good prediction.
Resistance of GCs to Aβ
A remarkable finding was a relative resistance of GCs to Aβ accumulation. Thus, when sections were processed with an antibody to Aβ that allows one to detect oligomeric (soluble, intracellular) forms of Aβ, as well as amyloid deposited extracellularly (McSA1 or thioflavin-S), staining was negligible in GCs. This result was not because the antibody or thioflavin-S was not able to detect intracellular or extracellular Aβ, because adjacent hilar neurons exhibited robust intracellular Aβ as did CA1. Furthermore, the findings were reproduced with two other antibodies to Aβ.
This result is important because, taken together with the neuroprotective effects of BDNF, GC resistance could be due, at least in part, to their ability to keep producing BDNF. However, the high activity of GCs in Tg2576 mice boosts production of other protective substances such as NPY, as mentioned above. The findings are important because if one can understand the resistance of GCs to Aβ accumulation it might be possible to use that knowledge to delay or prevent Aβ accumulation in vulnerable cells.
Additional considerations
An important consideration is that the anti-BDNF antibodies could detect the precursor to BDNF, proBDNF, as well as mature BDNF. This is important because the stability of MF BDNF with age could be due to a rise in proBDNF. Another consideration is BDNF receptors. Thus, a rise in MF BDNF may not increase BDNF functionally if BDNF receptors, which include full-length TrkB and truncated isoforms of TrkB, decline. There is data in normal rats suggesting that TrkB mRNA declines with age (Croll et al., 1998). Other studies suggest that full-length TrkB changes somewhat (Lapchak et al., 1993), and truncated isoforms decline (Silhol et al., 2005). However, in AD the changes in TrkB may differ from normal aging (Ginsberg et al., 2019). Indeed, truncated isoforms increase in the 5xTg AD mouse model rather than declining (Nitzan et al., 2022).
Conclusions
The results suggest that a decline in BDNF levels does not occur in all of the regions of the hippocampus in the Tg2576 AD mouse model. In particular, the impairments in learning and memory that involve GCs and the MFs are unlikely to be a result of reduced BDNF protein levels. Nevertheless, it is still possible that strategies to increase BDNF, which have been proposed (Nagahara et al., 2009; Rahman et al., 2023) may be therapeutic, and may be related to activity dependence, which is still understudied in AD and AD-relevant animal models.
Footnotes
Authors report no competing of financial interest.
This study was supported by NIH R01 AG908305 and R01 AG077103 and the New York State Office of Mental Health.
This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.